Abstract
Purpose
Radiotherapy-induced xerostomia (RIX) is the most common permanent side effect of radiotherapy (RT) to the head and neck (H&N). There is no effective topical treatment. LMS-611 is a mimetic of a natural lamellar body which prevents thick secretions like saliva from congesting organs. The primary objective of this study was to assess saliva properties before and during RT to the H&N. The secondary objectives were to re-assess saliva properties with the addition of LMS-611, measure inter-patient variability, correlate patient-reported symptoms with laboratory measurements and design subsequent first-in-human clinical trial of LMS-611.
Methods
Patients with H&N cancer receiving RT as primary treatment were recruited. Patients completed the Groningen RIX (GRIX) questionnaire and provided saliva samples at baseline and weeks 2, 4 and 6 of RT. Saliva adhesiveness and viscosity were tested by measuring time taken to travel 5 cm down an inclined plane.
Results
Thirty patients were enrolled. The inclined plane test (IPT) results (s) were as follows: baseline 31.3, week 2 49.7, week 4 51.1 and week 6 55.7. Wide inter-patient variability was seen at baseline. GRIX scores increased as RT progressed. Spearman rank correlation coefficient of inclined plane tests with GRIX scores was −0.06 at baseline, 0.25 at week 2, 0.12 at week 4 and 0.08 at week 6. LMS-611 concentrations of 10 and 20 mg/ml significantly reduced IPT times on saliva samples.
Conclusions
Saliva becomes more visco-adhesive and RIX worsens as RT progresses. There is little correlation between objective and subjective measures of RIX. The addition of LMS-611 to thick, sticky saliva restores its fluidity ex vivo. This warrants in vivo analysis of the effect of LMS-611 upon RIX.
Similar content being viewed by others
References
Bhide SA, Nutting CM (2010) Advances in radiotherapy for head and neck cancer. Oral Oncol 46(6):439–441
Jensen AB, Hansen O, Jorgensen K, Bastholt L (1994) Influence of late side-effects upon daily life after radiotherapy for laryngeal and pharyngeal cancer. Acta Oncol 33(5):487–491
Bjordal K, Kaasa S (1995) Psychological distress in head and neck cancer patients 7–11 years after curative treatment. Br J Cancer; 71(3):592–597
Dirix P, Nuyts S, Vander Poorten V, Delaere P, Van Den Bogaert W (2008) The influence of xerostomia after radiotherapy on quality of life. Results of a questionnaire in head and neck cancer. Support Care Cancer 16(2):171–179
Dirix P, Nuyts S, Van den Bogaert W (2006) Radiation-induced xerostomia in patients with head and neck cancer: a literature review. Cancer 107(11):2525–2534
Makkonen TA, Tenovuo J, Vilja P, Heimdahl A (1986) Changes in the protein composition of whole saliva during radiotherapy in patients with oral or pharyngeal cancer. Oral Surg Oral Med Oral Pathol 62(3):270–275
Wijers OB, Levendag PC, Braaksma MM, Boonzaaijer M, Visch LL, Schmitz PI (2002) Patients with head and neck cancer cured by radiation therapy: a survey of the dry mouth syndrome in long-term survivors. Head Neck; 24(8):737–747
Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R (2011) Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev (12)
Mehanna H, Jones TM, Gregoire V, Ang KK (2010) Oropharyngeal carcinoma related to human papilloma virus. BMJ 340:c1439
Gillison ML, Harris J, Westra W, et al (2009) Survival outcomes by tumour human papilloma virus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. J Clin Oncol ASCO Meet Abstr 27(15S):6003
Fakhry C, Westra WH, Li S, Cmelak A, et al (2008) Improved survival of patients with human papilloma virus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100(4):261–269
Ang KK, Harris J, Wheeler R et al (2010) Human papilloma virus and survival of patients with oropharyngeal cancer. N Engl J Med Jul 1;363(1):24–35.
Goldstein DP, Hynds Karnell L, Christensen AJ, Funk GF (2007) Health-related quality of life profiles based on survivorship status for head and neck cancer patients. Head Neck 29(3):221–229
Semple C (2001) The role of the CNS in head and neck oncology. Nurs Stand 15(23):39–42
Little M, Schipper M, Feng FY, et al (2012) Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands. Int J Radiat Oncol Biol Phys 83(3):1007–1014
Vissink A, Mitchell JB, Baum BJ, et al (2010) Clinical management of salivary gland hypofunction and xerostomia in head-and neck cancer patients: successes and barriers. Int J Radiat Oncol Biol Phys 78(4):983–991
Gregoire V, Coche E, Cosnard G, Hamoir M, Reychler H (2000) Selection and delineation of lymph node target volumes in head and neck conformal radiotherapy. Proposal for standardizing terminology and procedure based on the surgical experience. Radiother Oncol 56(2):135–150
Beetz I, Burlage FR, Henk P, et al (2010) The Groningen Radiotherapy-Induced Xerostomia Questionnaire: development and validation of a new questionnaire. Radiother Oncol 97:127–131
R Core Team (2013). R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria URL http://www.R-projectorg/. Accessed Sep 2014
Freitas DA, Caballero AD, Pereira MM, et al (2011) Oral sequelae of head and neck radiotherapy. CEFAC 13(6):1103–1108
Franzen L, Funegård U, Ericson T, Henriksson R (1992) Parotid gland function during and following radiotherapy of malignancies in the head and neck: a consecutive study of salivary flow and patient discomfort. Eur J Cancer 28(2–3):457–462
Dreizen S, Daly TE, Drane JB, Brown LR (1977) Oral complications of cancer radiotherapy. Postgrad Med 61(2):85–92
Wescott WB, Mira JG, Starcke EN, Shannon IL, Thornby JI (1978) Alterations in whole saliva flow rate induced by fractionated radiotherapy. Am J Roentgenol 130(1):145–149
Shannon IL, Trodahl JN, Starcke EN (1978) Radio sensitivity of the human parotid gland. Proc Soc Exp Biol Med 157(1):50–53
Mira JG, Wescott WB, Starcke EN, Shannon IL (1981) Some factors influencing salivary function when treating with radiotherapy. Int J Radiat Oncol Biol Phys 7(4):535–541
Konings AWT, Coppes RP, Vissink A (2005) On the mechanism of salivary gland radio sensitivity. Int J Radiat Oncol Biol Phys 62(4):1187–1194
Porter S, Scully C, Hegarty AM (2004) An update of the etiology and management of xerostomia. Oral Med Oral Surg Oral Pathol 97(1):28–46
Villa A, Abati S (2011) Risk factors and symptoms associated with xerostomia: a cross-sectional study. Aust Dent J 56:290–295
Thomson WM (2015) Dry mouth and older people. Aust Dent J 60(1 Suppl):54–63
Zuabi O, Machtei EE, Ben Aryeh H, et al (1999) The effect of smoking and periodontal treatment on salivary composition in patients with established periodontitis. J Periodontal 70:1240–1246
Kolte AP, Kolte RA, Laddha RK (2012) Effect of smoking on salivary composition and periodontal status. Indian Soc Periodontol 16(3):350–353
https://clinicaltrials.gov/ct2/show/NCT02123511?term=GRIX&rank=1. https://clinicaltrials.gov/ct2/show/NCT01823445?term=GRIX&rank=2. Accessed Oct 2014
Tiwana MS, Mahajan MK, Uppal B, Koshy G, Sachdeva J, Lee HN, Talole SD (2011) Whole saliva physico-biochemical changes and quality of life in head and neck cancer patients following conventional radiation therapy: a prospective longitudinal study. Indian J Cancer 48(3):289–295
Meirovitz A, Murdoch-Kinch CA, Schipper M, Pan C, Eisbruch A (2006) Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys 66(2):445–453
Lovelace TL, Fox NF, Sood AJ, et al (2014) Management of radiotherapy-induced salivary hypofunction and consequent xerostomia in patients with oral or head and neck cancer: meta-analysis and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol 117(5):595–607
Chaushu G, Bercovici M, Dori S, Waller A, Taicher S, Kronenberg J, Talmi YP (2000) Salivary flow and its relation with oral symptoms in terminally ill patients. Cancer 88(5):984–987
Nutting CM, Morden JP, Harrington KJ, et al (2011) Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 12:127–136
Setton J, Caria N, Romanyshyn J, et al (2012) Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Centre experience. Int J Radiat Oncol Biol Phys 82(1):291–298
Kam M, Leung SF, Zee B (2007) Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 25(31):4873–4879
Online document (2013) The radiotherapy innovation fund. An evaluation of the Prime Minister’s £23 million fund. http://www.cancerresearchuk.org/prod_consump/groups/cr_common/@nre/@pol/documents/generalcontent/rifevalreport.pdf. Accessed Oct 2014
Trotti A, Eisbruch A (2011) Reducing xerostomia through advanced technology. Lancet Oncol 12:110
MASCC Oral care study group. Summary of the oral complications systematic reviews. http://www.mascc.org/oral-care. Accessed Apr 2015
Acknowledgments
The authors acknowledge Graham Park, Head of Technical Development, Lamellar Biomedical Limited, who contributed to the study design and saliva sample analysis but sadly passed away prior to study completion.
Authors’ contributions
The following authors contributed to the study design: R Jones, J Paul and C Bray (all Cancer Research UK Clinical Trials Unit, Beatson WoSCC), and N Brittain and J Lang (NHS Greater Glasgow & Clyde Research & Development Department).
A McConnachie (Robertson Centre for Biostatistics, University of Glasgow) contributed to the statistical analysis.
Staff funding was provided by Scottish Cancer Research Network and NHS Research Scotland Career Researcher Fellowship, both from Chief Scientists Office, Scottish Government Health Directorate.
A James (Beatson WoSCC) and A J Chalmers (Institute of Cancer Sciences, University of Glasgow) provided assistance with the preparation of the manuscript.
Conflict of interest
Funding for this study was provided by Lamellar Biomedical Limited. Dr. Claire Paterson has no conflicts of interests to declare and had full access to all of the primary data. Review of the data by the journal is welcome.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Online Resource 1
(MPG 35854 kb)
Online Resource 2
(MPG 26868 kb)
Rights and permissions
About this article
Cite this article
Paterson, C., Caldwell, B., Porteous, S. et al. Radiotherapy-induced xerostomia, pre-clinical promise of LMS-611. Support Care Cancer 24, 629–636 (2016). https://doi.org/10.1007/s00520-015-2823-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-015-2823-5